B+
Bull case
25%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
BHC
Bausch Health CompaniesANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$7.25
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.80
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-09
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+81.9
Score
AI commentary
News tone is moderately positive after the Q2 results and guidance raise, while third-party coverage described improving earnings estimates. Exact post-release price reaction, analyst target revisions, options skew, short interest, employee sentiment, and social coverage are unavailable; missing data is not positive evidence. Overall, this supports cautious bullish monitoring rather than high-conviction accumulation.
RankAlpha Sentiment Codex - 2026-09-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-29eventQ2 results and FY2026 guidance raiseHigh impact
Bausch reported Q2 revenue of $2.85 billion, adjusted EPS of $1.26, adjusted EBITDA of $1.075 billion, and raised full-year 2026 revenue, adjusted EBITDA, and adjusted cash-flow guidance [#SEC-8K-2026-07-29].
2026-12-01catalystCash-flow conversion and debt-reduction follow-throughMedium impact
Q2 operating cash flow was $517 million and adjusted cash flow from operations was $471 million; continued cash generation and net-debt reduction could improve financial flexibility [#SEC-8K-2026-07-29].
2026-12-01catalystSecond-half commercial and gross-to-net pressureHigh impact
Third-party coverage cited potential pressure from gross-to-net accrual changes, Aplenzin loss of exclusivity, and erosion in Medicaid and former 340B revenue [#PR-EARNINGS-2026-08-21].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-09 • Updated nightlySource: Internal modelMethodology